Study S002161

Exenatide (Byetta) Vs Pramlintide (Symlin): Role in Post-prandial Hyperglycemia

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01269047
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 37
Start: 2009-08
Primary completion: 2016-08
Lead sponsor: Albert Einstein College of Medicine
Conditions: Type 1 Diabetes
Interventions: DRUG:Pramlintide; DRUG:Exenatide; DRUG:Insulin
Results posted: TRUE
Secondary identifiers: NIH:R01DK077166

Registered primary outcomes

Post-prandial Blood Glucose Concentration in Both Pramlintide and Exenatide Treated Groups in Acute and Chronic Setting, Compared to Insulin Monotherapy in Type 1 Diabetes Mellitus. [6 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.